

## Information on candidates nominated for election or re-election to the board

### New election

#### **Bo Jesper Hansen**

Born 1958. MD with a Ph.D. from Copenhagen University. Board member since 2010, Chairman since 2010. Other appointments: Chairman of SOBI, Board member of Hyperion Therapeutics Inc., GenSpera Inc., MipSalus ApS, TopoTarget A/S, Zymenex A/S, Orphazyme A/S and CMC Kontrast AB. Previous appointments: Various positions in Swedish Orphan International AB since 1993, CEO 1998 – 2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holding in Karolinska Development

### Re election

#### **Hans Wigzell**

Chairman and Board member since 2006. Born 1938. MD and Professor of Immunology. Other appointments Chairman of Rhenman & Partner Asset Management AB. Board member of Hyperion Therapeutics Inc., GenSpera Inc., AviBiopharma Inc., Swedish Orphan Biovitrum AB, Humalabs LLC, Intercell AG and RaySearch Laboratories AB. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of the Smittskyddsinstitutet.

Independent of the company and its senior management, as well as of major shareholders in the company.

Holdings in Karolinska Development 8 491 shares.

#### **Rune Fransson**

Board member since 2006. Born 1947. BSc. in Economics. Other appointments Chairman of Karolinska Institutet Holding AB and the University Accommodation Center AB. Previous assignments include, among others, Board member of KI Health Management.

Independent of the company and its senior management. Not independent of major shareholders in the company.

No holdings in Karolinska Development.

## **Per-Olof Edin**

Board member since 2007. Born 1940. Professor. Other appointments Board member of Axelar AB on behalf of the Baltic Sea Foundation. Previous assignments include, among others, Vice Chairman of the Seventh AP Fund, Chairman of Södertörn University College and the Baltic Sea Foundation.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development

## **Charlotte Edenius**

Board member since 2012. Born 1958. PhD., Medical Degree. Other appointments Executive VP Research & Development at Medivir AB, Director of the Board of Qlucore AB. Previous appointments include Senior VP Preclinical & Clinical R&D at Orexo AB, CSO at Biolipox AB, several positions within Clinical R&D at AstraZeneca as well as academic research at Karolinska Institutet and Board Member of Karolinska Institutet Innovations AB.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

## **Klaus Wilgenbus**

Board member since 2012. Born 1962. MD. Other appointments Corporate Senior Vice President Business Development / Licensing & Strategy of Boehringer Ingelheim GmbH. Previous appointments include several management positions within Boehringer Ingelheim GmbH, including Senior Vice President Licensing, Vice President R&D Licensing and Director for Exploratory Research in Oncology at Boehringer Ingelheim's R&D Centre in Vienna as well as academic research at Stanford University and the German Cancer Research Centre, Heidelberg.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

## **Vlad Artamonov**

Board member since 2012. Born 1978. MBA, B.Sc. Other appointments Board Member of Redbank Energy Ltd. and of Coastal Capital International Ltd., Managing Partner at Coastal Capital International Ltd. Previous appointments include Investment Analyst at Greenlight Capital Inc., position in the Global Merger & Acquisition Group at Merrill Lynch in New York.

Independent of the company and its senior management, as well as of major shareholders in the company.

Holdings in Karolinska Development 3,470,541 shares (by related legal person).